 This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subjects optimal dose administered once daily qd for a total of 12 weeks of treatment in pediatric subjects with TS. 